Complete enrollment for the CATALYST Phase 4 trial
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Feb 2023
- Due
- 31 Dec 2023
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Planned enrollment is 1,000 patients, which we expect to complete by the end of this year.”
What we found
Evidence strength A What the grades mean
The company's filings from February 2024 indicate that enrollment for the CATALYST trial was still ongoing, meaning the commitment to complete enrollment by the end of 2023 was not met.
-
A Corcept Therapeutics Inc. 8-K filed 2024-02-15
“CATALYST – Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes; patients with hypercortisolism may enter a randomized, double-blind, placebo-controlled study of Korlym – enrollment continues” ✓ confirmed on the page
Market reaction: the shares moved -6.3% against the S&P 500 over the three sessions around the disclosure (14 Feb 2024 to 20 Feb 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- CATALYST trial enrollment
- Target
- 1,000 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-CORT-002866 · Corrections policy